Brian McKeon Net Worth

The estimated Net Worth of Brian P Mckeon is at least 24.1 百万$ dollars as of 5 August 2024. Mr. Mckeon owns over 192 units of Idexx Laboratories stock worth over 15,221,592$ and over the last 21 years he sold IDXX stock worth over 4,960,125$. In addition, he makes 3,940,310$ as Chief Financial Officer、 Executive Vice President、 Treasurer at Idexx Laboratories.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McKeon IDXX stock SEC Form 4 insiders trading

Brian has made over 53 trades of the Idexx Laboratories stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 192 units of IDXX stock worth 94,130$ on 5 August 2024.

The largest trade he's ever made was exercising 249,412 units of Idexx Laboratories stock on 9 May 2011 worth over 6,901,230$. On average, Brian trades about 5,936 units every 43 days since 2003. As of 5 August 2024 he still owns at least 31,048 units of Idexx Laboratories stock.

You can see the complete history of Mr. Mckeon stock trades at the bottom of the page.

Brian McKeon biography

Brian P. McKeon serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. Mr. McKeon has been Executive Vice President, Chief Financial Officer and Treasurer since January 2014. He leads our finance, corporate development and worldwide operations functions. Mr. McKeon served as a Director of IDEXX from July 2003 through December 2013, including serving as Chair of the Audit Committee and as a member of the Compensation Committee. He also served as a Director of athenahealth, Inc. from September 2017 to February 2019. Mr. McKeon was Executive Vice President of Iron Mountain Incorporated from April 2007 to December 2013 and Chief Financial Officer of Iron Mountain from April 2007 to October 2013. Mr. McKeon was also Executive Vice President and Chief Financial Officer of The Timberland Company from March 2000 to April 2007. From 1991 to 2000, Mr. McKeon held several finance and strategic planning positions with PepsiCo, Inc., serving most recently as Vice President, Finance, at Pepsi-Cola, North America. Mr. McKeon holds a bachelor’s degree in accounting from the University of Connecticut and an M.B.A. with high distinction from Harvard University.

What is the salary of Brian McKeon?

As the Chief Financial Officer、 Executive Vice President、 Treasurer of Idexx Laboratories, the total compensation of Brian McKeon at Idexx Laboratories is 3,940,310$. There are 2 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of 8,309,800$.

How old is Brian McKeon?

Brian McKeon is 57, he's been the Chief Financial Officer、 Executive Vice President、 Treasurer of Idexx Laboratories since 2014. There are 13 older and 10 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.

What's Brian McKeon's mailing address?

Brian's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.

Insiders trading at Idexx Laboratories

Over the last 22 years, insiders at Idexx Laboratories have traded over 238,711,289$ worth of Idexx Laboratories stock and bought 24,695 units worth 3,109,424$ . The most active insiders traders include Stuart Essig、Johnny D Powers、Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of 4,641,291$. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth 234,685$.

What does Idexx Laboratories do?

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Complete history of Mr. Mckeon stock trades at Alkermes plc、Idexx Laboratories、Iron Mountain

Idexx Laboratories executives and stock owners

Idexx Laboratories executives and other stock owners filed with the SEC include:

• Jonathan Ayers,
  Director
• Jonathan Mazelsky,
  President, Chief Executive Officer, Director
• Brian McKeon,
  Chief Financial Officer, Executive Vice President, Treasurer
• Kathy Turner,
  Corporate Vice President and Chief Marketing Officer
• Jonathan J. Mazelsky,
  Pres, CEO & Director
• Sharon Underberg,
  Corporate Vice President, General Counsel, and Corporate Secretary
• Michael Lane,
  Executive Vice President, General Manager, Reference Laboratories and Information Technology
• Brian P. McKeon,
  CFO, Exec. VP & Treasurer
• Giovani Twigge,
  Chief Human Resource Officer, Corporate Vice President
• Dr. Nimrata Khatra Hunt P.E., Ph.D.,
  Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations
• Michael J. Lane,
  Exec. VP and GM of Reference Laboratories & Information Technology
• James F. Polewaczyk,
  Exec. VP & Chief Commercial Officer
• Sharon E. Underberg,
  Exec. VP, Gen. Counsel, & Corp. Sec.
• Lawrence Kingsley,
  Independent Chairman of the Board
• M. Anne Szostak,
  Independent Director
• Daniel Junius,
  Independent Director
• Bruce Claflin,
  Independent Director
• Rebecca Henderson,
  Independent Director
• Sophie Vandebroek,
  Independent Director
• Stuart Essig,
  Independent Director
• Sam Samad,
  Independent Director
• Jonathan W. Ayers,
  Sr. Advisor & Director
• Asha Collins,
  Independent Director
• James Polewaczyk,
  Executive Vice President and Chief Commercial Officer
• Tina Hunt,
  Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations
• Dr. Martin Smith Ph.D.,
  Exec. VP & CTO
• Ken Grady,
  Sr. VP & Chief Information Officer
• Martin Smith,
  Exec. VP & CTO
• Jeffery D. Chadbourne,
  Sr. Director of Accounting & Financial Reporting
• John Hart,
  Sr. VP of Worldwide Operations
• Barry C Johnson,
  Director
• Thomas Craig,
  Director
• William End,
  Director
• Jacqueline Studer,
  CVP, Gen. Counsel & Secretary
• Thomas J Dupree,
  Corporate Vice President
• Michael J Williams,
  Corporate Vice President
• Daniel V Meyaard,
  Corporate Vice President
• Conan R Deady,
  Vice President and Secretary
• Joseph V Vumbacco,
  Director
• William E Iii Brown,
  Corporate Vice President
• William B. Goodspeed,
  Corporate Vice President
• Robert J Murray,
  Director
• Jeffrey Fiarman,
  EVP, GEN COUNSEL & SECRETARY
• Ali Naqui,
  Vice President
• Johnny D Powers,
  Corporate Vice President
• Errol B Desouza,
  Director
• William C Wallen,
  SVP & Chief Scientific Officer
• Quentin J Tonelli,
  Vice President
• S Sam Fratoni,
  Vice President
• Irene C Kerr,
  Corporate Vice President
• Robert S Hulsy,
  Vice President
• Laurel E Labauve,
  Vice President
• Merilee Raines,
  Vice President,CFO & Treasurer
• James L Jr Moody,
  Director
• Jennifer A Joiner,
  Corp VP CAG N American CommOps
• Louis W Pollock,
  Senior Vice President
• Erwin R Jr Workman,
  Executive Vice President
• Nimrata Hunt,
  Executive Vice President
• Irene Chang Britt,
  Director
• Martin Alexander Smith,
  Executive Vice President
• Michael Perkins Johnson,
  EVP and CHRO
• George Fennell,
  SVP, Chief Revenue Officer
• Michael G Erickson,
  Executive Vice President
• Michael Schreck,
  Executive Vice President